adenomyosis
Conditions
Interventions
Surgical group:Laparoscopic adenomyosis foci resection
Postoperative injection of GnRh-a for 6 cycles:Laparoscopic adenomyosis resection + postoperative injection of GnRh-a for 6 cycles
Intraoperative placement of LNG-IUS:Laparoscopic adenomyosis resection + intraoperative placement of LNG-IUS
Sponsors
International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiaotong University
Eligibility
Sex/Gender
Female
Age
20 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1. The patient's age is 20-45 years old, and the patient is not postmenopausal. 2. The menstrual cycle is between 21-35 days, and the menstrual period is 3-7 days; 3. The VAS score of dysmenorrhea is =7 points; or the MVJ of menorrhagia is =5 points. 4. Preoperative imaging ultrasonography and MRI showed adenomyosis, which was confirmed by postoperative pathology. 5. Lesion resection for adenomyosis is the first operation. 6. Complete follow-up data. 7. Ability to cooperate with observation of curative effect and adverse events, as well as record the subject's daily reporter. 8. Those who gave informed consent and voluntarily participated in this clinical trial and signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Combined with uterine fibroids and the diameter of uterine fibroids is =5cm. 2. Combined with uterine submucosal fibroids. 3. Those with malignant diseases (endometrial cancer, ovarian cancer, breast cancer, etc.). 4. Patients with serious diseases such as cardiovascular and cerebrovascular, liver, kidney, diabetes, tumor, etc.; 5. Mental patients and long-term drinking or taking drugs affect cognition; 6. Pregnancy test positive, pregnant or lactating women, and those planning pregnancy; 7. Allergic constitution and known allergy to the components of this drug; 8. Those who have participated in other clinical trials or are participating in clinical trials within 3 months before screening; 9. Those who are considered unsuitable to participate in this clinical trial by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Pain level VAS score;Menstrual flow assessment MVJ score;Postoperative uterine volume;Cancer antigen-125;Peripheral blood miRNA;blood routine; | — |
Countries
China
Contacts
Public ContactFeng Sun
International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiaotong University
Outcome results
None listed